Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

Glycopyrrolate is now available in the company’s Simplist™ ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio. It is the first FDA-approved manufacturer-supplied ready-to-administer prefilled syringe for this medication in the U.S. 

Adenosine, a drug used in critical care settings, is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes. Fresenius Kabi now offers the broadest portfolio of Adenosine Injection.

The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

Methocarbamol Injection is the newest addition to the company´s anesthesia and analgesia portfolio.

Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira^® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira^® is a registered trademark of AbbVie Biotechnology Ltd.

Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira^® is a registered trademark of AbbVie Biotechnology Ltd.

Leucovorin Calcium is the newest addition to the company’s large oncology portfolio.

Omegaven® is an intravenous lipid emulsion that provides calories and fatty acids. In the U.S. it is indicated for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. With Omegaven® Fresenius Kabi provides the first and only FDA-approved fish oil lipid emulsion for this condition.